Ascendis Pharma A/S (NASDAQ:ASND) Reaches New 12-Month High – Should You Buy?

Ascendis Pharma A/S (NASDAQ:ASND) hit a new 52-week high on Monday . The company traded as high as $208.16 and last traded at $204.50, with a volume of 38815 shares trading hands. The stock had previously closed at $205.91.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on ASND shares. Bank of America lifted their price objective on shares of Ascendis Pharma A/S from $227.00 to $230.00 and gave the company a “buy” rating in a research note on Tuesday, September 2nd. Wells Fargo & Company reaffirmed an “overweight” rating and set a $295.00 target price (up from $289.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Wall Street Zen lowered Ascendis Pharma A/S from a “buy” rating to a “hold” rating in a report on Friday, September 5th. Cowen reaffirmed a “buy” rating on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Finally, UBS Group reaffirmed a “buy” rating and set a $307.00 target price (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $244.36.

Ascendis Pharma A/S Stock Performance

The stock has a 50 day moving average of $183.95 and a two-hundred day moving average of $168.66. The stock has a market cap of $12.42 billion, a PE ratio of -39.32 and a beta of 0.39.

Ascendis Pharma A/S (NASDAQ:ASND) last issued its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.49. The company had revenue of $216.28 million during the quarter, compared to analysts’ expectations of $163.17 million. Analysts expect that Ascendis Pharma A/S will post -4.34 EPS for the current fiscal year.

Hedge Funds Weigh In On Ascendis Pharma A/S

A number of institutional investors have recently bought and sold shares of the stock. Perceptive Advisors LLC purchased a new position in Ascendis Pharma A/S during the 2nd quarter valued at about $166,367,000. T. Rowe Price Investment Management Inc. grew its stake in Ascendis Pharma A/S by 12.0% during the 1st quarter. T. Rowe Price Investment Management Inc. now owns 3,053,824 shares of the biotechnology company’s stock valued at $475,970,000 after acquiring an additional 328,278 shares in the last quarter. Adage Capital Partners GP L.L.C. purchased a new position in Ascendis Pharma A/S during the 1st quarter valued at about $51,029,000. Vestal Point Capital LP grew its stake in Ascendis Pharma A/S by 108.0% during the 4th quarter. Vestal Point Capital LP now owns 520,000 shares of the biotechnology company’s stock valued at $71,588,000 after acquiring an additional 270,000 shares in the last quarter. Finally, RA Capital Management L.P. grew its stake in Ascendis Pharma A/S by 1.7% during the 1st quarter. RA Capital Management L.P. now owns 10,281,496 shares of the biotechnology company’s stock valued at $1,602,474,000 after acquiring an additional 168,752 shares in the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.